Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients

Mei Ru Chen, Mei Ying Liu, Shih Mei Hsu, Chin Chu Fong, Chien Jen Chen, I. How Chen, Mow Ming Hsu, Czau Siung Yang, Jen Yang Chen

Research output: Contribution to journalJournal Article peer-review

23 Scopus citations

Abstract

EBV serological tests have been used for many years as accessory diagnostic predictors of nasopharyngeal carcinoma (NPC). To increase the sensitivity and specificity of the NPC detection rate, a novel enzyme-linked immunosorbent assay (ELISA) was established using a bacterially-expressed GST-EBNA-1 protein, containing the EBNA-1 sequence cloned from an NPC patient. Serum samples were collected from age- and gender-matched patients with NPC, community control subjects and hospital control patients and tested using this ELISA. The positivity rates were 78.7% (247/314) in NPC, 11.5% (28/244) in hospital controls and 3.8% (10/263) in the community control group. These serum samples were also tested for IgA anti-VCA antibodies and their ability to neutralize EBV DNase and the sensitivities of the anti-VCA antibody and DNase-neutralization tests also were analyzed. The optimum combination is VCA plus EBNA-1, which can identify 92.5% (287/310) of NPC patients, and shows a specificity of 92.7% (242/261) for normal individuals.

Original languageEnglish
Pages (from-to)51-57
Number of pages7
JournalJournal of Medical Virology
Volume64
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Antibodies
  • EBNA-1
  • NPC

Fingerprint

Dive into the research topics of 'Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients'. Together they form a unique fingerprint.

Cite this